Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
Understanding Myeloma News About Secondary Cancers and Clotting
About admin
View all posts by adminSubscribe
Subscribe to our e-mail newsletter to receive updates.
James R. Berenson, MD
- President & CEO, Institute for Myeloma & Bone Cancer Research (IMBCR)
- President & Medical Director. Berenson Cancer Center (Berensoncancercenter)
- Founder & President, ONCOtherapeutics
- Founder & Principal, ONCOtracker
-
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
-
IMBCR & Emory University’s Big Discovery!!!
-
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
- What Is Multiple Myeloma?
-
Video Updates
- Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
- Understanding Myeloma News About Secondary Cancers and Clotting
-
Dedication of “Determination”
May 28, 2012
Press Releases